|
1
|
Dela Cruz CS, Tanoue LT and Matthay RA:
Lung cancer: epidemiology, etiology, and prevention. Clin Chest
Med. 32:605–644. 2011.PubMed/NCBI
|
|
2
|
NSCLC Meta-Analysis Collaborative Group.
Chemotherapy in addition to supportive care improves survival in
advanced non-small-cell lung cancer. A systemic review and
meta-analysis of individual patient data from 16 randomized
controlled trials. J Clin Oncol. 26:4617–4625. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Simon GR, Ismail-Khan R and Bepler G:
Nuclear excision repair-based personalized therapy for non-small
cell lung cancer: from hypothesis to reality. Int J Biochem Cell
Biol. 39:1318–1328. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jordheim LP, Sève P, Trédan O, et al: The
ribonucleotide reductase large subunit (RRM1) as a predictive
factor in patients with cancer. Lancet Oncol. 12:693–702. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stewart DJ: Tumor and host factors that
may limit efficacy of chemotherapy in non-small cell and small cell
lung cancer. Crit Rev Oncol Hematol. 75:173–234. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bepler G, Sharma S, Gautam A, et al: Tumor
genotype, RRM1 expression and outcome of patients with lung cancer.
Eur J Cancer. 38(Suppl 7): 82(Abstr 265). 2003.
|
|
7
|
Vilmar A and Sorensen JB: Excision repair
cross-complementation group 1 (ERCC1) in platinum-based treatment
of non-small cell lung cancer with special emphasis on carboplatin:
a review of current literature. Lung Cancer. 64:131–139. 2009.
View Article : Google Scholar
|
|
8
|
Olaussen K, Dunant A, Fouret P, et al: DNA
repair by ERCC1 in non-small-cell lung cancer and cisplatin-based
adjuvant chemotherapy. N Engl J Med. 335:981–983. 2006.PubMed/NCBI
|
|
9
|
Ceppi P, Volante M, Novello S, et al:
ERCC1 and RRM1 gene expression but not EGFR are predictive of
shorter survival in advanced non-small-cell lung cancer treated
with cisplatin and gemcitabine. Ann Oncol. 17:1818–1825. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Paz-Ares L, Souliers D, Melezinek I, et
al: Clinical outcome in non-small cell lung cancer patients with
EGFR mutation: pooled analysis. J Cell Mol Med. 14:51–69.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mitsudomi T, Morita S, Yatabe Y, et al:
Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): an open label, randomized phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
|
|
12
|
Zheng Z, Chen T, Li X, et al: DNA
synthesis and repair genes RRM1 and ERCC1 in lung
cancer. N Engl J Med. 356:800–808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bepler G, Olaussen KA, Vataire AL, et al:
ERCC1 and RRM1 in the international adjuvant lung trial by
automated quantitative in situ analysis. Am J Pathol.
178:69–78. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cobo M, Isla D, Massuti B, et al:
Customizing cisplatin based on quantitative excision repair
cross-complementing 1 mRNA expression: a phase III trial in
non-small-cell lung cancer. J Clin Oncol. 25:2747–2754. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Simon GR, Schell MJ, Begum M, et al:
Preliminary indication of survival benefit from ERCC1 and
RRM1-tailored chemotherapy in patients with advanced
non-small cell lung cancer: evidence from an individual patient
analysis. Cancer. 118:2525–2531. 2012.PubMed/NCBI
|
|
16
|
McWhinney SR and McLeod HL: Using germline
genotype in cancer pharmacogenetic studies. Pharmacogenomics.
10:489–493. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bepler G, Zheng Z, Gautam A, et al:
Ribonucleotide reductase M1 gene promoter activity, polymorphisms,
population frequencies, and clinical relevance. Lung Cancer.
47:183–192. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang PM, Tzeng CH, Chen PM, et al:
ERCC1 codon 118 C→T polymorphism associated with
ERCC1 expression and outcome of FOLFOX-4 treatment in Asian
patients with metastatic colorectal carcinoma. Cancer Sci.
100:278–283. 2009. View Article : Google Scholar
|
|
19
|
Isla D, Sarries C, Rosell R, et al: Single
nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated
advanced non-small-cell lung cancer. Ann Oncol. 15:1194–1203. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tibaldi C, Giovannetti E, Vasile E, et al:
Correlation of CDA, ERCC1, and XPD polymorphisms with response and
survival in gemcitabine/cisplatin-treated advanced non-small cell
lung cancer patients. Clin Cancer Res. 14:1797–1803. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ryu JS, Hong YC, Han HS, et al: Associated
between polymorphisms of ERCC1 and XPD and survival in
non-small-cell lung cancer patients treated with cisplatin
combination chemotherapy. Lung Cancer. 44:311–316. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Su D, Ma S, Liu P, et al: Genetic
polymorphisms and treatment response in advanced non-small cell
lung cancer. Lung Cancer. 56:281–288. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Krawczyk P, Wojas-Krawczyk K, Mlak R, et
al: Predictive value of ERCC1 single-nucleotide polymorphism in
patients receiving platinum-based chemotherapy for locally-advanced
and advanced non-small cell lung cancer: a pilot study. Folia
Histochem Cytobiol. 50:80–86. 2012. View Article : Google Scholar
|
|
24
|
Ren S, Zhou S, Wu F, et al: Association
between polymorphisms of DNA repair genes and survival of advanced
NSCLC patients treated with platinum-based chemotherapy. Lung
Cancer. 75:102–109. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kalikaki A, Kanaki M, Vassalou H, et al:
DNA repair gene polymorphisms predict favorable clinical outcome in
advanced non-small-cell lung cancer. Clin Lung Cancer. 10:118–123.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu D, Shi J, Sun T, et al: Pharmacogenetic
role of ERCC1 genetic variants in treatment response of
platinum-based chemotherapy among advanced non-small cell lung
cancer patients. Tumour Bio. 33:877–884. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takenaka T, Yano T, Kiyohara C, et al:
Effects of excision repair cross-complementation group 1 (ERCC1)
single nucleotide polymorphisms on the prognosis of non-small cell
lung cancer patients. Lung Cancer. 67:101–107. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ludovini V, Floriani I, Pistola L, et al:
Association of cytidine deaminase and xeroderma pigmentosum group D
polymorphisms with response, toxicity, and survival in
cisplatin/gemcitabine-treated advanced non-small cell lung cancer
patients. J Thorac Oncol. 6:2018–2026. 2011. View Article : Google Scholar
|
|
29
|
Liao WY, Shih JY, Chang GC, et al: Genetic
polymorphism of XRCC1 Arg399Gln is associated with survival in
non-small-cell lung cancer patients treated with
gemcitabine/platinum. J Thorac Oncol. 7:973–981. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Feng JF, Wu JZ, Hu SN, et al:
Polymorphisms of the ribonucleotide reductase M1 gene and
sensitivity to platin-based chemotherapy in non-small cell lung
cancer. Lung Cancer. 66:344–349. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Song D, Ai-Lin G, Zhi-Hong Ch, et al: RRM1
single nucleotide polymorphism −37C>A correlates with
progression-free survival in NSCLC patients after gemcitabine-based
chemotherapy. J Hematol Oncol. 3:102010.
|
